Shares Held by Insiders

Fully Diluted Shares Held by Insiders

Date

Name

Buy/Sell

$ Value

# Shares

Avg. Price

Title

Chief Executive Officer

Chief Financial Officer

CHIEF LEGAL OFFICER &

CHIEF EXECUTIVE OFFICER

PRESIDENT & CHIEF OPERATING

See Remarks

President & COO

Ligand Pharmaceuticals Incorporated, a biopharmaceutical company, focuses on developing or acquiring technologies that help pharmaceutical companies to discover and develop medicines worldwide. Its commercial programs include Kyprolis and Evomela, which are used to treat multiple myeloma; Veklury for the treatment of moderate or severe COVID-19; Teriparatide injection product for osteoporosis; Vaxneuvance for the prevention of invasive disease caused by Streptococcus pneumoniae serotypes; and Pneumosil, a pneumococcal conjugate vaccine to help fight against pneumococcal pneumonia among children. The company also offers Rylaze, a recombinant erwinia asparaginase for the treatment of acute lymphoblastic leukemia or lymphoblastic lymphoma in adult and pediatric patients; Nexterone, a captisol-enabled formulation of amiodarone; and Zulresso, a captisol-enabled formulation of brexanolone for the treatment of postpartum depression. In addition, it provides Noxafil-IV, a captisol-enabled formulation of posaconazole for IV use; Duavee for the treatment of post-menopausal symptoms in women; Exemptia for autoimmune diseases; Vivitra for breast cancer; and Bryxta and Zybev for various indications. The company has alliances, licenses, and other business relationships with Amgen, Merck, Pfizer, Jazz, Takeda, Gilead Sciences, and Baxter International. Further, it sells Captisol materials. Ligand Pharmaceuticals Incorporated was incorporated in 1987 and is based in San Diego, California.

Ligand Pharmaceuticals Incorporated, a biopharmaceutical company, focuses on developing or acquiring technologies that help pharmaceutical...

Datesorted ascending	Name	Buy/Sell	$ Value	# Shares	Avg. Price	Title
2024-04-24	Premium	acquired	Premium	Premium	Premium	-
2024-03-25	Premium	acquired	Premium	Premium	Premium	Chief Executive Officer
2024-03-05	Premium	acquired	Premium	Premium	Premium	-
2024-03-05	Premium	acquired	Premium	Premium	Premium	-
2024-03-05	Premium	sold	Premium	Premium	Premium	-
2024-02-28	Premium	sold	Premium	Premium	Premium	Chief Financial Officer
2024-02-28	Premium	acquired	Premium	Premium	Premium	Chief Financial Officer
2024-02-27	Premium	acquired	Premium	Premium	Premium	Chief Financial Officer
2024-02-27	Premium	acquired	Premium	Premium	Premium	CHIEF LEGAL OFFICER &
2024-02-27	Premium	acquired	Premium	Premium	Premium	CHIEF EXECUTIVE OFFICER
2024-02-27	Premium	acquired	Premium	Premium	Premium	PRESIDENT & CHIEF OPERATING
2024-02-15	Premium	sold (taxes)	Premium	Premium	Premium	CHIEF LEGAL OFFICER &
2024-02-15	Premium	sold (taxes)	Premium	Premium	Premium	CHIEF EXECUTIVE OFFICER
2024-02-15	Premium	sold (taxes)	Premium	Premium	Premium	PRESIDENT & CHIEF OPERATING
2024-02-15	Premium	sold (taxes)	Premium	Premium	Premium	Chief Financial Officer
2024-01-02	Premium	sold (taxes)	Premium	Premium	Premium	PRESIDENT & CHIEF OPERATING
2023-12-29	Premium	acquired	Premium	Premium	Premium	CHIEF LEGAL OFFICER &
2023-12-05	Premium	sold (taxes)	Premium	Premium	Premium	Chief Financial Officer
2023-12-05	Premium	sold (taxes)	Premium	Premium	Premium	PRESIDENT & CHIEF OPERATING
2023-10-01	Premium	sold (taxes)	Premium	Premium	Premium	Chief Financial Officer
2023-09-22	Premium	acquired	Premium	Premium	Premium	-
2023-09-22	Premium	bought	Premium	Premium	Premium	CHIEF EXECUTIVE OFFICER
2023-08-10	Premium	sold (taxes)	Premium	Premium	Premium	CHIEF LEGAL OFFICER &
2023-06-30	Premium	acquired	Premium	Premium	Premium	PRESIDENT & CHIEF OPERATING
2023-06-30	Premium	acquired	Premium	Premium	Premium	Chief Financial Officer

LGND - Ligand Pharmaceuticals Inc Stock Price, Fair Value and News

Latest Insider Trading transactions for LGND